SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-21-020166
Filing Date
2021-04-05
Accepted
2021-04-05 17:22:50
Documents
12
Period of Report
2021-05-19

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT def14a_aditxthera.htm DEF 14A 1875433
2 GRAPHIC taditxt_logo.jpg GRAPHIC 61233
3 GRAPHIC tkingsdale_logo.jpg GRAPHIC 33590
4 GRAPHIC tsig_001.jpg GRAPHIC 20457
5 GRAPHIC tmail.jpg GRAPHIC 7140
6 GRAPHIC tinternet.jpg GRAPHIC 6836
7 GRAPHIC tphone.jpg GRAPHIC 7423
8 GRAPHIC tmembers.jpg GRAPHIC 6877
9 GRAPHIC tproxy_001.jpg GRAPHIC 699233
10 GRAPHIC tproxy_002.jpg GRAPHIC 421468
11 GRAPHIC tproxy_003.jpg GRAPHIC 1244980
12 GRAPHIC tproxy_004.jpg GRAPHIC 1024227
  Complete submission text file 0001213900-21-020166.txt   6641916
Mailing Address 2569 WYANDOTTE, ST. SUITE 101 MOUNTAIN CA 94043
Business Address 2569 WYANDOTTE, ST. SUITE 101 MOUNTAIN CA 94043 909-488-0844
Aditx Therapeutics, Inc. (Filer) CIK: 0001726711 (see all company filings)

IRS No.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39336 | Film No.: 21806680
SIC: 2834 Pharmaceutical Preparations